Brian Liu
Principal; Vice President @ Longitude Capital
Stanford, United States
Brian Liu is a Series B investor at Longitude Capital in Stanford focused on Biotechnology and Health Care. Dr. Liu is a Vice President at Longitude Capital. Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company, where he advised clients in the biotechnology and medical device industries. Dr. Liu is a board observer at Inflazome. Dr. Liu holds an M.D.from Stanford School of Medicine and a B.S. in Biomedical Engineering from The Johns Hopkins University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Brian Liu invests in
Stages Brian Liu invests in
Countries Brian Liu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (100%)
- Health Care 1 (33%)
- Life Science 1 (33%)
- Therapeutics 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Series B 1 (33%)
- Series D 1 (33%)
- Series E 1 (33%)
Country
- United States 2 (67%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alentis Therapeutics
|
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $181.4M / Series D / Nov 12, 2024 | |
Lassen Therapeutics
|
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis, and blocking its activity has the potential to be moreeffective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. | $85M / Series B / Dec 19, 2023 | |
CG Oncology
|
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $120M / Series E / Nov 15, 2022 |
Co-Investors
About Longitude Capital
Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance the quality of life, and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles.Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from the initial investment.Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments.
Longitude Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amar Patel
Associate
|
|||
|
Brian Liu
Principal; Vice President
|
|||
David Hirsch
Managing Director
|
|||
Juliet Tammenoms Bakker
Co-Founder and Managing Director
|
|||
Karthik Bolisetty
Associate
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brian Liu invest in?
Brian Liu invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brian Liu?
Public channels for Brian Liu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brian Liu last invest?
The most recent investment recorded for Brian Liu closed in Nov 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
